Molecular basis and outcomes of atypical haemolytic uraemic syndrome in Czech children

被引:6
作者
Stolbova, Sarka [1 ,2 ]
Bezdicka, Martin [1 ,2 ]
Prohaszka, Zoltan [3 ,4 ]
Csuka, Dorottya [3 ,4 ]
Hrachovinova, Ingrid [5 ]
Burkert, Jan [2 ,6 ]
Simankova, Nadezda [1 ,2 ]
Pruhova, SStepanka [1 ,2 ]
Zieg, Jakub [1 ,2 ]
机构
[1] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague, Czech Republic
[2] Motol Univ Hosp, Prague, Czech Republic
[3] Hungarian Acad Sci, Dept Med 3, Budapest, Hungary
[4] Hungarian Acad Sci, MTA SE Res Grp Immunol & Haematol, Budapest, Hungary
[5] Inst Hematol & Blood Transfus, Prague, Czech Republic
[6] Charles Univ Prague, Fac Med 2, Dept Cardiovasc Surg, Prague, Czech Republic
关键词
Alternative complement pathway; Anti-complement factor H antibodies; Atypical haemolytic uraemic syndrome; Children; DGKE; Next-generation sequencing; FACTOR-H-AUTOANTIBODIES; COMPLEMENT MUTATIONS; ECULIZUMAB; IMPACT; GENE; CFHR1;
D O I
10.1007/s00431-020-03666-9
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Atypical haemolytic uraemic syndrome is an ultra-rare, life-threatening disease. Causative variants in genes that encode complement factors can be identified in 40-70% of cases. We performed genetic analysis of 21 Czech children with atypical haemolytic uraemic syndrome. Genetic or acquired predisposition to the disease was identified in the majority of our patients: CFHR1 and CFHR3 deletions in 14/21 (67%; 13 of them were positive for anti-complement factor H antibodies), variants in complement genes or DGKE in 13/21 (62%). Multiple genetic findings were identified in eight patients (38%). The incidence of atypical haemolytic uraemic syndrome in the Czech paediatric population was estimated to be 0.092 (CI 0.053-0.131) cases per million inhabitants and 0.92 (CI 0.53-1.32) cases per 100,000 births for the entire reporting period. Ten patients were initially treated with plasma exchange and eight with eculizumab or with a combination of eculizumab and plasma exchange. At the last follow-up, 20 patients were alive and one patient had end-stage renal disease. Conclusion: The incidence of atypical haemolytic uraemic syndrome in the Czech paediatric population corresponds to the reported incidence in Europe. We detected the unusually high rate of CFHR1/CFHR3 deletions associated with anti-complement factor H antibodies in Czech paediatric patients. Treatment by eculizumab led to superior outcomes and prevention of the disease relapses compared with plasma exchange therapy. Our results may help to understand the polygenic nature of atypical haemolytic uraemic syndrome as a disease that results from a combination of various risk factors.What is Known: center dot Atypical haemolytic uraemic syndrome (aHUS) is considered a polygenic and multifactorial disease. Genetic predisposition to aHUS is identified in 40-70% of children. center dot Anti-complement factor H antibodies are usually found in 6-25% of affected children.What is New: center dot Potentially causative genetic or acquired factors were confirmed in the majority of patients. The prevailing finding was the unusually high rate of CFHR1/CFHR3 deletions associated with anti-complement factor H antibodies (62% of patients). center dot The incidence of aHUS in Czech children is 0.092 (CI 0.053-0.131) cases per million inhabitants and 0.92 (CI 0.53-1.32) cases per 100,000 births for the entire reporting period.
引用
收藏
页码:1739 / 1750
页数:12
相关论文
共 50 条
  • [21] Atypical haemolytic uraemic syndrome in a child with cystic fibrosis
    Wong, Matthew D.
    Patel, Chirag
    McTaggart, Steven
    Wainwright, Claire E.
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2022, 58 (03) : 532 - 535
  • [22] Changing strategies for organ transplantation in atypical haemolytic uraemic syndrome: A tertiary case series
    Forbes, Thomas A.
    Bradbury, Mark G.
    Goodship, Tim H. J.
    McKiernan, Patrick J.
    Milford, David V.
    PEDIATRIC TRANSPLANTATION, 2013, 17 (03) : E93 - E99
  • [23] Adverse outcomes in obstetric-atypical haemolytic uraemic syndrome: a case series analysis
    Kozlovskaya, Natalia L.
    Korotchaeva, Yulia V.
    Bobrova, Larisa A.
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2019, 32 (17) : 2853 - 2859
  • [24] Treatment and management of children with haemolytic uraemic syndrome
    Walsh, Patrick R.
    Johnson, Sally
    ARCHIVES OF DISEASE IN CHILDHOOD, 2018, 103 (03) : 285 - 291
  • [25] Absence of thrombocytopaenia and/or microangiopathic haemolytic anaemia does not reliably exclude recurrence of atypical haemolytic uraemic syndrome after kidney transplantation
    Krishnan, Anoushka R.
    Siva, Brian
    Chakera, Aron
    Wong, Germaine
    Wong, Daniel
    Lim, Wai H.
    NEPHROLOGY, 2017, 22 : 28 - 31
  • [26] Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS)
    Wong, Edwin
    Challis, Rachel
    Sheerin, Neil
    Johnson, Sally
    Kavanagh, David
    Goodship, Timothy H. J.
    IMMUNOBIOLOGY, 2016, 221 (06) : 715 - 718
  • [27] A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
    Rathbone, John
    Kaltenthaler, Eva
    Richards, Anna
    Tappenden, Paul
    Bessey, Alice
    Cantrell, Anna
    BMJ OPEN, 2013, 3 (11):
  • [28] Atypical haemolytic uraemic syndrome: a case of rare genetic mutation
    Sangeetha, Geminiganesan
    Jayaraj, Jaippreetha
    Ganesan, Swathi
    Puttagunta, Sreeapoorva
    BMJ CASE REPORTS, 2021, 14 (07)
  • [29] Eculizumab: A Review of Its Use in Atypical Haemolytic Uraemic Syndrome
    Gillian M. Keating
    Drugs, 2013, 73 : 2053 - 2066
  • [30] Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases
    Nester, Carla M.
    Brophy, Patrick D.
    CURRENT OPINION IN PEDIATRICS, 2013, 25 (02) : 225 - 231